NEKTAR THERAPEUTICS (NKTR) Stock Price, Quote, News and Overview
NASDAQ:NKTR - Nasdaq - US6402681083 - Common Stock - Currency: USD
NKTR Quote, Performance and Key Statistics
25.76
-3.92 (-13.21%)
The current stock price of NKTR is 25.76 USD. In the past month the price increased by 132.26%. In the past year, price increased by 38.49%.
NKTR Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| LLY | ELI LILLY & CO | 56.36 | 734.92B | ||
| JNJ | JOHNSON & JOHNSON | 15.17 | 366.71B | ||
| NVO | NOVO-NORDISK A/S-SPONS ADR | 18.57 | 304.42B | ||
| NVS | NOVARTIS AG-SPONSORED ADR | 14.44 | 237.03B | ||
| AZN | ASTRAZENECA PLC-SPONS ADR | 15.87 | 216.57B | ||
| MRK | MERCK & CO. INC. | 10.15 | 198.62B | ||
| PFE | PFIZER INC | 7.54 | 137.53B | ||
| SNY | SANOFI-ADR | 10.49 | 116.45B | ||
| BMY | BRISTOL-MYERS SQUIBB CO | 6.31 | 94.33B | ||
| GSK | GSK PLC-SPON ADR | 8.54 | 78.19B | ||
| ZTS | ZOETIS INC | 25.94 | 69.53B | ||
| TAK | TAKEDA PHARMACEUTIC-SP ADR | 62.92 | 47.17B |
Related stock screener links
About NKTR
Company Profile
Nektar Therapeutics is a biotechnology company, which engages in the discovery and development of novel therapies which selectively modulate the immune system to treat autoimmune disorders. The company is headquartered in San Francisco, California and currently employs 61 full-time employees. The company is focused on developing treatments that address the underlying immunological dysfunction in autoimmune and chronic inflammatory diseases. In oncology, it is focused on developing medicines based on targeting biological pathways that stimulate and sustain the body’s immune response to fight cancer. Its lead product candidate, rezpegaldesleukin (REZPEG, or NKTR-358), is a novel regulatory T cell stimulator being evaluated in two Phase IIb clinical trials, one in atopic dermatitis and one in alopecia areata. Its pipeline also includes a preclinical bivalent tumor necrosis factor receptor type II (TNFR2) antibody and bispecific programs, NKTR-0165 and NKTR-0166, and a modified hematopoietic colony stimulating factor (CSF) protein, NKTR-422. The company is also evaluating NKTR-255, an investigational IL-15 receptor agonist designed to boost the immune system's natural ability to fight cancer, in several ongoing clinical trials.
Company Info
NEKTAR THERAPEUTICS
455 Mission Bay Boulevard South
San Francisco CALIFORNIA 94158 US
CEO: Howard W. Robin
Employees: 61
Phone: 18554826587
NEKTAR THERAPEUTICS / NKTR FAQ
What is the stock price of NEKTAR THERAPEUTICS today?
The current stock price of NKTR is 25.76 USD. The price decreased by -13.21% in the last trading session.
What is the ticker symbol for NEKTAR THERAPEUTICS stock?
The exchange symbol of NEKTAR THERAPEUTICS is NKTR and it is listed on the Nasdaq exchange.
On which exchange is NKTR stock listed?
NKTR stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for NEKTAR THERAPEUTICS stock?
14 analysts have analysed NKTR and the average price target is 75.23 USD. This implies a price increase of 192.02% is expected in the next year compared to the current price of 25.76. Check the NEKTAR THERAPEUTICS stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is NEKTAR THERAPEUTICS worth?
NEKTAR THERAPEUTICS (NKTR) has a market capitalization of 4.79B USD. This makes NKTR a Mid Cap stock.
How many employees does NEKTAR THERAPEUTICS have?
NEKTAR THERAPEUTICS (NKTR) currently has 61 employees.
Is NEKTAR THERAPEUTICS (NKTR) expected to grow?
The Revenue of NEKTAR THERAPEUTICS (NKTR) is expected to decline by -56.58% in the next year. Check the estimates tab for more information on the NKTR EPS, Sales, EBIT and EBITDA future analyst estimates.
Should I buy NEKTAR THERAPEUTICS (NKTR) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of NKTR, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of NKTR, evaluating the profitability, health, valuation and growth aspects
- NEKTAR THERAPEUTICS (NKTR) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- NEKTAR THERAPEUTICS (NKTR) Sales and EPS estimates to see what analysts future expectations are.
- NEKTAR THERAPEUTICS (NKTR) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- NEKTAR THERAPEUTICS (NKTR) Insider and Institutional Ownership to learn about the owners and their transactions.
- NEKTAR THERAPEUTICS (NKTR) Stock Chart to make your own analysis
- NEKTAR THERAPEUTICS (NKTR) Latest news and press-releases to stay up to date.
Does NEKTAR THERAPEUTICS (NKTR) stock pay dividends?
NKTR does not pay a dividend.
When does NEKTAR THERAPEUTICS (NKTR) report earnings?
NEKTAR THERAPEUTICS (NKTR) will report earnings on 2025-08-06, after the market close.
What is the Price/Earnings (PE) ratio of NEKTAR THERAPEUTICS (NKTR)?
NEKTAR THERAPEUTICS (NKTR) does not have a PE ratio as the earnings reported over the last twelve months were negative (-12.45).
NKTR Technical Analysis
ChartMill assigns a technical rating of 8 / 10 to NKTR. When comparing the yearly performance of all stocks, NKTR is one of the better performing stocks in the market, outperforming 96.56% of all stocks.
NKTR Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to NKTR. While NKTR seems to be doing ok healthwise, there are quite some concerns on its profitability.
NKTR Financial Highlights
Over the last trailing twelve months NKTR reported a non-GAAP Earnings per Share(EPS) of -12.45. The EPS increased by 9.78% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -51.92% | ||
| ROE | -968.42% | ||
| Debt/Equity | 0 |
NKTR Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 81% to NKTR. The Buy consensus is the average rating of analysts ratings from 14 analysts.
For the next year, analysts expect an EPS growth of -8.09% and a revenue growth -56.58% for NKTR